Nicolas Delanoy

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Nicolas Delanoy, Jean‐Marie Michot, Thibault Comont et al. · The Lancet Haematology · 2018 · 269 citations

Immunohematology, Autoimmune Disease, Lupus +12

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

Antoine Angelergues, Denis Maillet, Aude Fléchon et al. · European Journal of Cancer · 2014 · 53 citations

Urology, Oncology, Genitourinary Cancer +7

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database

Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou et al. · European Urology Oncology · 2018 · 31 citations

Urology, Genitourinary Cancer, Medicine +7

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial

Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Bécourt et al. · Gynecologic Oncology · 2023 · 27 citations

Neoadjuvant Chemotherapy, Medicine, Metronomic Therapy +8